With $334M in cash, Aerie preps to break even

With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham ’s Aerie Pharmaceuticals is prepped to break even. The company (Nasdaq: AERI) confirmed Tuesday that its current cash is sufficient to get it to its break-even point on its first quarter financial results call. After hiring and training a 100-person sales force, Aerie’s glaucoma drug Rhopressa officially launched last week in national and regional pharmaceutical distributors in the U.S. “We…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news